The GALT Investor Relations site contains information about Galectin Therapeutics Inc. clinical trials in NASH cirrhosis and cancer immunotherapy for ...
Investor Relations. Overview · Press Releases · Events & Presentations · Corporate Governance · Financial Information · Stock Information · FAQs · Email Alert ...
According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.16. The reported EPS for the same ...
Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%. Key Insights Galectin Therapeutics' ...
Missing: relations | Show results with:relations
Galectin Therapeutics (GALT) Investor Presentation - Slideshow · SA TranscriptsTue, Nov. 22, 2022. Galectin Therapeutics (GALT) Presents At H.C. Wainwright & Co ...
Missing: relations | Show results with:relations
The Investor Relations website contains information about Galectin Therapeutics Inc.'s business for stockholders, potential investors, and financial analysts. 2.
GALT - Galectin Therapeutics Inc. Stock - Stock Price ... Investor Shares, Geode Capital Management, Llc ... relation to this website or the information and ...